<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129258">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01672476</url>
  </required_header>
  <id_info>
    <org_study_id>A657-BR-CT-L301</org_study_id>
    <nct_id>NCT01672476</nct_id>
  </id_info>
  <brief_title>A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension</brief_title>
  <acronym>fimasartan</acronym>
  <official_title>A Randomized, Double-Blind, Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Konyang University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ilsan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daegu Fatima Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dong-A University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soon Chun Hyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eulji University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sejong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ewha Womans University Mokdong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jeju National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-Blind, Multicenter, phase III Study to Evaluate the Antihypertensive
      Efficacy and Safety of Fimasartan (BR-A-657·K) 30mg Compared to Placebo in Patients with
      Mild to Moderate Essential Hypertension
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After subjects have signed informed consent voluntarily, when they are taking hypertension
      medication, they go through screening period for 7 days including wash-out period.

      After screening and wash-out period, subjects take the placebo for 14 days (Maximum 21
      days), and evaluate their suitability to Inclusion and Exclusion criteria.

      Patients, who evaluated the proper subject for this clinical trial, are allocated to
      experimental group (Fimasartan 30mg) or Control group (Placebo group) or Reference group
      (Valsartan 80mg) randomly at a ratio 2:2:1 and their investigational drugs will be
      administered daily for the study period (8 weeks). Subjects visit their investigators twice
      during treatment period, when they take their investigational drugs for 4 weeks, and 8
      weeks.

      The placebo period will be single-blinded and the treatment allocation in this study will be
      double-blinded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>the difference of sitting DBP</measure>
    <time_frame>After 8 weeks from baseline visit</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To compare the difference of sitting DBP between fimasaratn 30mg group and placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the difference of sitting DBP</measure>
    <time_frame>After 8 weeks from baseline visit</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To compare the difference of sitting DBP between fimasaratn 30mg group and valsartan 80mg group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the difference of SiDBP</measure>
    <time_frame>After 4 weeks from baseline visit</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To compare the difference of SiDBP among fimasartan 30mg group, valsartan 80mg and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the difference of SiSBP</measure>
    <time_frame>After 4 weeks and 8 weeks from baseline visit</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To compare the difference of SiSBP among fimasartan 30mg group, valsartan 80mg and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the ratio of responder(SiDBP&lt;90mmHg or ΔSiDBP≥10mmHg)</measure>
    <time_frame>After 8 weeks from baseline visit</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To compare the ratio of responder(SiDBP&lt;90mmHg or ΔSiDBP≥10mmHg) among fimasartan 30mg group, valsartan 80mg and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the ratio of subjects who get normalized blood pressure(SiDBP&lt;90mmHg &amp; SiSBP&lt;140mmHg)</measure>
    <time_frame>After 8 weeks from baseline visit</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To compare the ratio of subjects who get normalized blood pressure(SiDBP&lt;90mmHg &amp; SiSBP&lt;140mmHg) among fimasartan 30mg group, valsartan 80mg and placebo group</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">275</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule/day of placebo will be orall administered for the study period (8 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 80mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(As reference group) 80mg/day of Valsartan will be orall administered for the study period (8 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg/day of Fimasartan will be orall administered for the study period (8 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Valsartan 80mg</description>
    <arm_group_label>Valsartan 80mg</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan</intervention_name>
    <description>Fimasartan 30mg</description>
    <arm_group_label>Fimasartan 30mg</arm_group_label>
    <other_name>Kanarb</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjecs who agreed to participate in this clinical trial and submitted the written
             informed consent

          2. Subjects aged 20 to 75 years

          3. Essential hypertension patients who are measured more 90mmHg, less than 110mmHg of
             sitting diastolic blood pressure(SiDBP) at baseline(Day 0)

          4. Subject who considered to understand this clinical trial, be cooperative,and able to
             be followed-up whole of the clinical trial period

        Exclusion Criteria:

          1. Severe hypertension patients: more 110mmHg of mean SiDBP and/or more 185mmHg of mean
             Sitting systolic blood pressure(SiSBP)

          2. Patients with orthostatic hypotension who has sign and symptom

          3. Patients with secondary hypertension

          4. Patients who are measured the difference of mean blood pressure of one arm under
             SiDBP 10mmHg or SiSBP 20mmHg at screening and baseline visit

          5. Patients who cannot stop administration of hypertension medication through the
             clinical trial period, and can take any other hypertension medication except
             investigational drugs

          6. Patients with significant investigations-abnormal renal function (Creatinine more 1.5
             times than upper limit of normal), abnormal liver function(AST, ALT more 2 times than
             upper limit of normal), severe fatty liver disease needed medication

          7. Patients with clinically significant investigations in laboratory test of screening
             visit

          8. Patients with surgical and medical disease that is able to be affect to absorption,
             distribution, metabolism and excretion

          9. Patients with severe insulin dependent or uncontrolled diabetes mellitus (HbA1c&gt;9,
             regimen change of oral hypoglycemic agent, using insulin)

         10. Patients with severe heart disease, ischemic heart disease within 6 months,
             peripheral vascular disease, Percutaneous transluminal coronary angiography(PTCA),
             Coronary artery bypass graft(CABG)

         11. Patients with significant ventricular tachycardia, atrial fibrillation, atrial
             flutter or other significant arrhythmia

         12. Patients with hypertrophic obstructive cardiomyopathy, severe obstructive coronary
             artery disease, aortic stenosis, hemodynamically significant aortic valve or mitral
             valve disease

         13. Patients with severe cerebrovascular disease

         14. Patients with wasting disease, autoimmune disease, connective tissue disease at
             present and/or previous

         15. Patients with known severe or malignancy retinopathy

         16. Patients with hepatitis B or C or HIV positive reaction

         17. Patients with the medical histories of malignant tumor within 5 years,except local
             basal cell carcinoma of the skin

         18. Patients who have a story or evidence of alcohol or drug abuse within 2 years

         19. Patients with history of allergic reaction to any angiotensin II antagonist

         20. Patients with any chronic inflammation disease needed to chronic inflammation therapy

         21. Childbearing and breast-feeding women

         22. Femal who plan to become pregnancy or have a possibility of pregnancy but don't
             prevent conception with acknowledged methods

         23. Patients who took medicine within 12 weeks from screening visit or is going on the
             progress of other clinical trial

         24. Patients with significant investigations-Hypokalemia(Less than 3.5 mmol/L),
             Hyperkalemia(exceeded 5.5 mmol/L)

         25. Patients with sodium ion or body fluid is deplated and not able to correct

         26. Subject who are judged unsuitable to participate in this clinical trial by
             investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seok Min Kang, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seong Hee Lee, Director</last_name>
    <phone>82-2-708-8069</phone>
    <email>shlee07@boryung.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>So Jin Kim, Project Manager</last_name>
    <phone>82-2-740-4341</phone>
    <email>kimsojin@boryung.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seok-min Kang, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>September 4, 2012</lastchanged_date>
  <firstreceived_date>August 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fimasartan</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
